Description of the medicine: Molragostim (Molgramostim)

MOLGOGRASIM (Molgramostim) *.

Synonyms: Leicomax, Leucomax [name of the drug company "Sandoz" (Switzerland)].

Molgrastim has a certain immunotropic activity; It stimulates the growth of T-lymphocytes (but not B-lymphocytes). The main specific property of the moldrail is its ability to stimulate leukopoiesis, therefore it is used as an antileukopenic agent.

Until recently, there were not enough effective specific anti-leukopenic agents. To a certain extent leukopoiesis stimulates leucogen, methylthiouracil, pentoxyl, and batilol (see). To stimulate leukopoiesis, immunostimulating preparations of thymalin, sodium nucleate and others are also used.

The recent creation of the Moldrahm was an important contribution to the therapy of leukopenia. This drug is a recombinant (obtained by genetic engineering) human granulocyte-macrophage colony-stimulating factor. Thus, mollegostim is an endogenous factor involved in the regulation of hematopoiesis and the functional activity of leukocytes. It stimulates the proliferation and differentiation of hematopoietic cell precursors, as well as the growth of granulocytes, monocytes; Increases the content of mature cells in the blood.

The drug leukomax (mollegostim) is a highly purified water-soluble protein consisting of 127 amino acid residues. Leucomax is used to treat and prevent leukopenia in pathological conditions, accompanied by a violation of myelogenous hematopoiesis. The drug accelerates the recovery of myeloid hematopoiesis; Contributes to the prevention of potential infectious complications of leukopenia.

Doses and the scheme of administration of the drug depend on the indications and the course of the pathological process.

With aplastic (hypoplastic) anemia, 3 μg / kg (0.003 μ / kg) is injected under the skin once a day. The therapeutic effect usually occurs after 2 to 4 days, after which the dose is selected individually so as to maintain the number of leukocytes at the desired level, usually not more than 10 * 10 9 / L.

With leukopenia, which occurred during chemotherapy tumors, injected under the skin 5 - 10 mcg / kg once a day. The drug begins to enter 1 day after the end of the cycle of chemotherapy. Simultaneously with chemotherapy, leukomax is not used. Enter leukomax in these doses for 7 to 10 days.

The cycle of chemotherapy is repeated 48 hours after the cessation of leukomax injection.

Apply leukomax also in the treatment of AIDS patients. With monotherapy injected under the skin 1 mcg / kg once a day; When combined with specific antiviral drugs (see Ganciclovir) - 1 to 3 - 5 μg / kg per day. The effect is usually observed on day 2 - 4. Then the dose is selected individually (every 3 to 5 days) to maintain the number of leukocytes at the desired level, usually not more than 10 * 10 9 / L.

When bone marrow transplantation is administered, 5 to 10 μg / kg of leukomax per day.